Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 11/20 | 0.42 |
| ▸ | MAOA | P21397 | 10/20 | 0.42 |
| ▸ | MAOB | P27338 | 10/20 | 0.42 |
| ▸ | CTSC | P53634 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11880622 | 0.90 | NPC1 (0.41) | MAPK1CYP2C19KDM1AMAOAMAOB | |
| SCHEMBL6624487 | 0.86 | KDM1A (0.43) | MAPK1CYP2C19KDM1AMAOAMAOB | |
| SCHEMBL15960825 | 0.82 | MAPT (0.43) | MAPK1CYP2C19KDM1AMAOAMAOB | |
| SCHEMBL669428 | 0.81 | GAA (0.47) | — | |
| SCHEMBL8861377 | 0.79 | DPP4 (0.40) | MAPK1CYP2C19CTSCCTSL | |
| SCHEMBL10073856 | 0.79 | RORC (0.42) | KDM1AMAOAMAOBCTSCCHRM1 | |
| SCHEMBL11209553 | 0.79 | SMN1; SMN2 (0.50) | CYP2C19CTSC | |
| SCHEMBL670171 | 0.79 | MEN1 (0.43) | KDM1A | |
| SCHEMBL670172 | 0.79 | MEN1 (0.43) | KDM1A | |
| SCHEMBL670182 | 0.72 | CTSC (0.46) | MAPK1CYP2C19CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046455-A1 | Catalytic Cyclopropanation of Alkenes with Alpha-Cyano-Diazoacetates | NATIONAL SCIENCE FOUNDATION | 2012-02-23 | — | — | US | disclosed |
| US-20120046455-A1 | Catalytic Cyclopropanation of Alkenes with Alpha-Cyano-Diazoacetates | NATIONAL SCIENCE FOUNDATION | 2012-02-23 | — | — | US | disclosed |
| EP-0015604-B1 | COMPOUNDS AND COMPOSITIONS FOR USE IN INHIBITION OF LIPOGENESIS IN MAMMALS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1983-02-23 | — | — | EP | disclosed |
| EP-0015604-A1 | Compounds and compositions for use in inhibition of lipogenesis in mammals | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1980-09-17 | — | — | EP | disclosed |
| US-4202902-A | VETERINARY MEDICINE | SHELL OIL COMPANY (US) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046455-A1 | Catalytic Cyclopropanation of Alkenes with Alpha-Cyano-Diazoacetates | PPOX, POR, PCCA | MAPK1 2618/4885CYP2C19 971/4885KDM1A 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.